Clinical DevelopmentVaregacestat has demonstrated strong depth of response with a mean best change from baseline tumor size of -45%, mean best change from baseline tumor volume of -87%, and T2W signal intensity of -94% with the selected Phase III 1.2mg QD dose.
Commercialization StrategyThe company intends on commercializing varegacestat in the US, Canada, and Europe, with external distributors in LATAM and Middle East, as well as partner(s) in Asia.
Financial StabilityThe company has a strong cash position with $317.3 million in cash and cash equivalents, providing a cash runway into 2027.